Datapoints: The ups and downs of dosing second-generation antipsychotics.
Citrome
Leslie
L
Department of Psychiatry, New York University School of Medicine, New York City, USA. citrome@nki.rfmh.org
Jaffe
Ari
A
Levine
Jerome
J
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D000068180:Aripiprazole; D000077152:Olanzapine